IMI work package 5: report 1:b:iii benefit - riskwave 1 case study report:Raptiva® (efalizumab)

Micaleff, A., Callreus, T., Phillips, L. D., Hughes, D., Hockley, K., Wang, N. & Luciani, D. (2013). IMI work package 5: report 1:b:iii benefit - riskwave 1 case study report:Raptiva® (efalizumab). PROTECT Consortium.

Copy

Item Type	Report (Technical Report)
Copyright holders	© 2013 PROTECT Consortium
Departments	LSE > Academic Departments > Management
Date Deposited	08 Dec 2015
URI	https://researchonline.lse.ac.uk/id/eprint/64631

Explore Further

Phillips, Lawrence D.

HD61 Risk Management
RS Pharmacy and materia medica
RZ Other systems of medicine

http://www.imi-protect.eu/documents/Micaleff_et_al_Benefit_Risk_Wave_Case_study_Report_Efalizumab_Feb_2013.pdf (Publisher)
http://www.lse.ac.uk/management/people/emeriti-visiting-staff/lphillips.aspx (Author)
http://www.imi-protect.eu/ (Official URL)

Full text not available from this repository.

Downloads

View more statistics

IMI work package 5: report 1:b:iii benefit - riskwave 1 case study report:Raptiva® (efalizumab)

Explore Further

Export as